Enabling in-house comprehensive genomic profiling for today's and tomorrow's clinical needs

Comprehensive Genomic Profiling (CGP) is becoming a critical component for evaluating treatment options in oncology patients.  The ideal CGP assay provides information on both standard-of-care and evolving molecular biomarkers, maximizes information obtained from limited biopsy samples, and is straightforward to implement and operate in the pathology laboratory.  In this workshop, Dr. Solomon from Weill Cornell shares his lab's experience implementing CGP using a hybrid capture based CGP assay and its impact at his institution. He describes considerations in choosing assays for implementation and will discuss the value of in-house comprehensive CGP assays.

Learning:

• Reasons and considerations for implementing CGP and value of a flexible future-proof DNA+RNA CGP in-house assay.
• Implementing and operating CGP assays for precision medicine solution
• Impact of CGP supporting oncology clinical and research

James P. Solomon, MD PhD
Medical Director, Clinical Genomics Laboratory
Assistant Professor of Pathology and Laboratory Medicine
Weill Cornell Medicine

Dr. James P. Solomon is the medical director of the clinical genomics laboratory at Weill Cornell Medicine / New York Presbyterian Hospital. The laboratory focuses on clinical molecular testing and next-generation sequencing of solid tumors. Dr. Solomon is board certified in molecular genetic pathology and anatomic and clinical pathology.